Marlan D. Walker - 05 Dec 2023 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
Chief Executive Officer
Signature
/s/ Marlan D. Walker
Issuer symbol
TXMD
Transactions as of
05 Dec 2023
Net transactions value
-$43,684
Form type
4
Filing time
07 Dec 2023, 16:51:56 UTC
Previous filing
04 May 2023
Next filing
20 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +70,000 +603% $0.000000 81,615 05 Dec 2023 Direct
transaction TXMD Common Stock Sale $33,496 -14,500 -18% $2.31 67,115 06 Dec 2023 Direct F1, F2
transaction TXMD Common Stock Sale $10,187 -4,550 -6.8% $2.24 62,565 07 Dec 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -70,000 -100% $0.000000* 0 05 Dec 2023 Common Stock 70,000 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023.